Scarica l'app Stockscreener
36.23
3.15%
-1.18
Dopo l'orario di chiusura:
36.22
-0.010
-0.03%
Precedente Chiudi:
$37.41
Aprire:
$37.25
Volume 24 ore:
500.62K
Relative Volume:
0.48
Capitalizzazione di mercato:
$2.27B
Reddito:
-
Utile/perdita netta:
$-229.97M
Rapporto P/E:
-8.38
EPS:
-4.3234
Flusso di cassa netto:
$-136.51M
1 W Prestazione:
-2.13%
1M Prestazione:
-19.83%
6M Prestazione:
+74.43%
1 anno Prestazione:
+922.00%
Intervallo 1D:
$36.01
$37.75
Intervallo di 1 settimana:
$32.93
$37.97
Portata 52W:
$3.26
$47.84
Kodiak Sciences Inc Stock (KOD) Company Profile
Nome
Kodiak Sciences Inc
Settore
Industria
Telefono
650-281-0850
Indirizzo
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
36.23 | 2.34B | 0 | -229.97M | -136.51M | -4.3234 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-25 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-09-22 | Iniziato | Jefferies | Buy |
| 2025-08-14 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-05 | Iniziato | H.C. Wainwright | Neutral |
| 2023-12-11 | Ripresa | Goldman | Sell |
| 2023-11-17 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-07-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-15 | Iniziato | CapitalOne | Overweight |
| 2022-08-02 | Downgrade | Citigroup | Neutral → Sell |
| 2022-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Iniziato | Goldman | Buy |
| 2022-02-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Iniziato | Evercore ISI | Outperform |
| 2021-03-01 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-11-30 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-03 | Iniziato | Goldman | Buy |
| 2020-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Iniziato | SunTrust | Buy |
| 2020-01-08 | Iniziato | ROTH Capital | Buy |
| 2020-01-03 | Iniziato | Jefferies | Buy |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-20 | Iniziato | Chardan Capital Markets | Buy |
| 2018-10-29 | Iniziato | Barclays | Overweight |
| 2018-10-29 | Iniziato | BofA/Merrill | Buy |
| 2018-10-29 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Kodiak Sciences Inc Borsa (KOD) Ultime notizie
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally - AOL.com
KOD Technical Analysis | Trend, Signals & Chart Patterns | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences Inc stock (US50012K1051): earnings loss widens as biotech pushes retina pipeline - AD HOC NEWS
Kodiak Sciences Inc stock (US50012K1051): what’s behind the latest volatility after eye disease se - AD HOC NEWS
Boxer Capital Management Boosts Kodiak Sciences Holdings in Q1 2026News and Statistics - IndexBox
Kodiak Sciences Inc stock (US50012K1051): Investors eye eye-disease pipeline after latest company up - AD HOC NEWS
Kodiak Sciences stock hits 52-week highhere's why - MSN
Kodiak Sciences (KOD) price target increased by 16.91% to 66.30 - MSN
Sirenia Capital (KOD) and Alex Silverstein report 3,495,000 shares (5.7%) - Stock Titan
Kodiak Sciences stock (US50012K1051): Q4 2025 earnings miss sparks investor focus - AD HOC NEWS
Kodiak Sciences (KOD) up 2% since last earnings report: Can it continue? - MSN
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Cuts Target Price to $56 - Moomoo
Number of shareholders of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Chardan Capital upgrades Kodiak Sciences (KOD) - MSN
TradingKey - TradingKey
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
KOD Upgraded by Chardan Capital -- Price Target Raised to $61.00 - GuruFocus
This Pitney Bowes Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
Chardan upgrades Kodiak Sciences stock rating on drug trial results By Investing.com - Investing.com South Africa
Chardan upgrades Kodiak Sciences stock rating on drug trial results - Investing.com
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Kodiak's Q1 loss wider than expected, pipeline development in focus - MSN
A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda - Yahoo Finance
Zenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD) - Yahoo Finance
Kodiak Sciences Zenkuda Data Shifts Focus To Retinal Pipeline Value - Sahm
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
KOD SEC FilingsKodiak Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
Kodiak Sciences 1Q Loss/Shr 94c >KOD - Moomoo
Kodiak Sciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Kodiak Sciences (NASDAQ: KOD) Q1 loss deepens as cash runway, going concern risk flagged - Stock Titan
Kodiak Sciences (NASDAQ: KOD) posts Q1 loss, highlights strong Phase 3 data - Stock Titan
Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
KOD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Press Release: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results - Moomoo
Kodiak Sciences (KOD) Expected to Announce Earnings on Wednesday - MarketBeat
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences - marketscreener.com
Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC - MarketBeat
Eye drug data from Taiwan cohort backs Kodiak Phase 3 expansion - Stock Titan
Kodiak Sciences Presents Pipeline Advances and KSI-101 Clinical Data At Scientific Conferences - marketscreener.com
Kodiak Sciences Inc Azioni (KOD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):